(CDAX, Industrial Goods & Services, FPH GR)



Done		Value Indicators:	EUR	Warburg ESG Risk Score:	2.4	Description:	
Buy		DCF:	6.01	ESG Score (MSCI based):	3.0	Manufacturer of franking mad	hinos
				Balance Sheet Score:	4.3	and provider of mail services.	
EUR <b>6.00</b>	(EUR 5.00)			Market Liquidity Score:	0.0		
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2022e
		Market cap:	44.5	Freefloat	50.67 %	Beta:	1.6
Price	EUR 2.88	No. of shares (m):	15.5	Obotritia Capital	28.01 %	Price / Book:	1.9 x
Upside	108.3 %	EV:	76.7	Active Ownership Fund	9.51 %	Equity Ratio:	14 %
-		Freefloat MC:	22.6	SALTARAX GmbH	5.00 %	Net Fin. Debt / EBITDA:	0.5 x
		Ø Trad. Vol. (30d):	18.30 th			Net Debt / EBITDA:	1.2 x

### Impressive comeback

Stated Figure	s Q4/2021	:						Comment on Figures:
in EUR m	Q4/21	Q4/21e	Q4/20	yoy	2021	2020	yoy	On April 28, 2022, Francotyp-Postalia Holding AG presented the
Sales	54.8	51.1	48.3	13.6%	203.7	195.9	4.0%	for the 2021 financial year.  These were above expectations, which was partly attributable to
EBITDA	3.2	8.0	-11.5	-	18.5	8.0	132.1%	stronger sales but also to lower costs as part of the ongoing restri
margin	5.9%	1.5%	-23.9%		9.1%	4.1%		in the fourth quarter.
EBIT	-2.4	-4.2	-16.5	-85.5%	-0.7	-14.0	-95.3%	
margin	-4.4%	-8.3%	-34.2%		-0.3%	-7.1%		

On the revenue side, the 2021 financial year was characterised by visible momentum in the area of digital business models (revenue increase of +14% from EUR 16.0m to EUR 18.4m) and the postal consolidation business (+9%, from EUR 58.2m to EUR 63.6m due to an increase in postage), while the core business with franking machines remained stable. Approximately 65% (62% in prior-year period) recurring revenue underlines FP's resilient business model. More interesting, however, is that the company managed to significantly reduce costs as planned. While the 2020 financial year was still dominated by restructuring, the 2021 financial year showed the first positive effects, a trend that will continue in 2022 and 2023. The most important aspects of FY 2021 were: The FUTURE@FP programme has improved the cost base (EUR 5.5m, target EUR 9m), the investment in One ERP, FP-Sign and IoT (EUR 1.8m) were expensed as incurred, a negative effect was included from cleaning up or discharging of "old" projects (ERP/CRM and IoT) in FY 2021 (EUR 2.8m).

On the basis of growing sales in attractive segments and, at the same time, a sharp reduction in costs, there are also excellent earnings prospects for the years to come. The communication within the framework of the presentation of the annual report essentially confirmed the attractive earnings expectations (WRe). On the basis of extremely attractive multiples (PE 2022 below 6x) and a price target of EUR 6.00 (5.00, roll-over, minor adjustments), the share continues to be rated Buy.

Changes in E	stimates:					
FY End: 31.12. in EUR m	2022e (old)	+ / -	2023e (old)	+/-	2024e (old)	+/-
Sales EBITDA	206.0 26.8	13.1 % 2.7 %	212.2 29.7	13.1 % 1.0 %	n.a. n.a.	n.m. n.m.
EBIT EPS	8.3 0.37	2.6 % 10.8 %	11.2 0.49	-0.1 % 8.2 %	n.a. n.a.	n.m. n.m.

### Comment on Changes:

- Slight increase in sales expectation owing to more optimistic business prospects and the consolidation of a small acquisition (Azolver GmbH) for the full year (vs. nine months in 2021).
- In terms of earnings, however, the acquisition has a neutral effect. Together with slightly higher cost base expectations, the earnings forecasts remain unchanged.
- Nonetheless, they continue to show a dramatic improvement over the previous year as a result of the restructuring efforts of recent years.




Rel. Perfor	mance vs CD	AX:
1 month:		11.5 %
6 months:		12.1 %
Year to date:		7.7 %
Trailing 12 m	onths:	1.6 %
_		

Company events:	
25.05.22	Q1
15.06.22	AGM
01.09.22	Q2
24.11.22	Q3

FY End: 31.12.	CAGR	2040	2040	2020	2024	2022	2022	2024-
in EUR m	(21-24e)	2018	2019	2020	2021	2022e	2023e	2024e
Sales	6.7 %	204.2	209.1	195.9	203.7	233.0	240.0	247.2
Change Sales yoy		-1.0 %	2.4 %	-6.3 %	4.0 %	14.4 %	3.0 %	3.0 %
Gross profit margin		57.0 %	60.3 %	55.8 %	53.8 %	53.5 %	53.5 %	53.5 %
EBITDA	18.7 %	17.1	33.3	8.0	18.5	27.5	30.0	30.9
Margin		8.4 %	15.9 %	4.1 %	9.1 %	11.8 %	12.5 %	12.5 %
EBIT	-	-0.3	5.9	-14.0	-0.7	8.5	11.2	11.4
Margin		-0.1 %	2.8 %	-7.1 %	-0.3 %	3.6 %	4.7 %	4.6 %
Net income	187.8 %	0.9	1.7	-15.2	0.4	6.6	8.5	8.7
EPS	200.0 %	0.06	0.11	-0.94	0.02	0.41	0.53	0.54
EPS adj.	200.0 %	0.06	0.11	-0.94	0.02	0.41	0.53	0.54
DPS	-	0.03	0.03	0.00	0.00	0.16	0.21	0.22
Dividend Yield		0.8 %	0.9 %	n.a.	n.a.	5.7 %	7.4 %	7.5 %
FCFPS		0.38	0.17	0.86	0.40	0.08	0.28	0.33
FCF / Market cap		10.1 %	5.0 %	26.3 %	13.0 %	2.7 %	9.6 %	11.4 %
EV / Sales		0.4 x	0.5 x	0.4 x	0.4 x	0.3 x	0.3 x	0.3 x
EV / EBITDA		5.0 x	2.9 x	10.6 x	4.5 x	2.9 x	2.6 x	2.4 x
EV / EBIT		n.a.	16.3 x	n.a.	n.a.	9.3 x	6.8 x	6.5 x
P/E		62.6 x	31.5 x	n.a.	154.2 x	7.0 x	5.4 x	5.3 x
P / E adj.		62.6 x	31.5 x	n.a.	154.2 x	7.0 x	5.4 x	5.3 x
FCF Potential Yield		2.2 %	10.0 %	-1.3 %	11.7 %	21.2 %	23.5 %	25.0 %
Net Debt		24.6	40.3	31.4	33.4	32.2	30.1	27.8
ROCE (NOPAT)		n.a.	2.6 %	n.a.	n.a.	10.9 %	13.0 %	12.5 %
Guidance:	Revenues EUI	R 229-237m	, EBITDA EU	R 24-28m (2	022)			

+49 40 309537-120






## **Company Background**

- Francotyp Postalia Holding AG, headquarted in Berlin, is a globally-active supplier of products and services for the postal market.
- The company was formed in 1983 with the merger of Francotyp (founded 1923) and Postalia (founded 1938) and has thus more than 80 years of experience in the postal market.
- Franking and inserting machines are still the core business activity.
- With new solutions e.g. In the field of IoT and electronic signature, the company strategically expanded its portfolio.

## **Competitive Quality**

- Focusing on customers with low to medium postal needs, Francotyp Postalia caters for two stable segments in the generally difficult market for franking machines.
- The 45% market share in the German market for franking machines demonstrates its reputation as the market leader in Germany based on the following distinguishing characteristics:
- established customer relationships and 80 years of experience in the German market with knowledge of customer demands and an efficient service network with rapid reaction times.
- The high proportion (about three-quarters) of recurring revenues as a share of total revenue underlines the successful transformation of the competitive quality into a high company quality.
- For new market entrants, Francotyp Postalia's existing customer base is an unachievable target and the franking machines niche is unattractive.





DCF model														
	Detailed	d forecas	t period				7	ransition	al period					Term. Value
Figures in EUR m	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	
Sales	233.0	240.0	247.2	254.6	262.2	270.1	278.2	286.6	295.2	304.0	313.1	322.5	332.2	
Sales change	14.4 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	1.0 %
EBIT	8.5	11.2	11.4	15.3	15.7	16.2	16.7	17.2	17.7	18.2	18.8	19.4	19.9	
EBIT-margin	3.6 %	4.7 %	4.6 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	
Tax rate (EBT)	32.0 %	32.0 %	32.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	
NOPAT	5.8	7.6	7.8	10.2	10.5	10.9	11.2	11.5	11.9	12.2	12.6	13.0	13.4	
Depreciation	19.0	18.8	19.5	22.9	23.6	21.6	22.3	20.1	20.7	21.3	21.9	22.6	23.3	
in % of Sales	8.2 %	7.8 %	7.9 %	9.0 %	9.0 %	8.0 %	8.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	
Changes in provisions	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1	
Change in Liquidity from														
- Working Capital	5.4	0.9	0.9	-2.2	8.0	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.1	
- Capex	21.0	24.0	24.0	28.0	26.2	24.3	19.5	20.1	20.7	21.3	21.9	22.6	23.3	
Capex in % of Sales	9.0 %	10.0 %	9.7 %	11.0 %	10.0 %	9.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-1.6	1.6	2.4	7.4	7.1	7.3	13.1	10.6	10.9	11.2	11.5	11.9	12.2	21
PV of FCF	-1.5	1.4	1.9	5.4	4.8	4.5	7.3	5.5	5.1	4.8	4.6	4.3	4.1	88
share of PVs		1.23 %						36.00	) %					62.77 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2034e	52		
				Terminal Value	88		
Debt ratio	20.00 %	Financial Strength	1.60	Financial liabilities	48		
Cost of debt (after tax)	2.1 %	Liquidity (share)	1.60	Pension liabilities	19		
Market return	7.50 %	Cyclicality	1.60	Hybrid capital	0		
Risk free rate	2.00 %	Transparency	1.60	Minority interest	0		
		Others	1.60	Market val. of investments	0		
				Liquidity	20	No. of shares (m)	15.5
WACC	9.06 %	Beta	1.60	Equity Value	93	Value per share (EUR)	6.01

Sens	itivity Va	lue per Sh	are (EUR	)													
		Terminal (	Growth								Delta EBIT	Γ-margin					
Beta	WACC	0.25 %	0.50 %	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.83	10.1 %	4.25	4.36	4.48	4.60	4.73	4.86	5.00	1.83	10.1 %	2.62	3.28	3.94	4.60	5.26	5.92	6.58
1.71	9.6 %	4.85	4.98	5.11	5.26	5.41	5.57	5.74	1.71	9.6 %	3.16	3.86	4.56	5.26	5.96	6.66	7.35
1.66	9.3 %	5.18	5.32	5.46	5.62	5.79	5.96	6.15	1.66	9.3 %	3.46	4.18	4.90	5.62	6.34	7.06	7.78
1.60	9.1 %	5.52	5.68	5.84	6.01	6.19	6.38	6.59	1.60	9.1 %	3.78	4.52	5.26	6.01	6.75	7.49	8.24
1.54	8.8 %	5.89	6.06	6.24	6.42	6.62	6.84	7.06	1.54	8.8 %	4.12	4.89	5.66	6.42	7.19	7.96	8.73
1.49	8.6 %	6.29	6.47	6.66	6.87	7.09	7.32	7.58	1.49	8.6 %	4.49	5.28	6.08	6.87	7.66	8.46	9.25
1.37	8.1 %	7.17	7.39	7.62	7.87	8.13	8.42	8.73	1.37	8.1 %	5.31	6.16	7.02	7.87	8.72	9.57	10.42

<sup>•</sup> Francotyp generates high steady cash flows in a normal business year.



Valuation							
	2018	2019	2020	2021	2022e	2023e	2024e
Price / Book	1.8 x	1.7 x	3.9 x	3.2 x	1.9 x	1.5 x	1.3 x
Book value per share ex intangibles	-0.46	-0.42	-1.60	-0.89	-0.67	-0.73	-0.82
EV / Sales	0.4 x	0.5 x	0.4 x	0.4 x	0.3 x	0.3 x	0.3 x
EV / EBITDA	5.0 x	2.9 x	10.6 x	4.5 x	2.9 x	2.6 x	2.4 x
EV / EBIT	n.a.	16.3 x	n.a.	n.a.	9.3 x	6.8 x	6.5 x
EV / EBIT adj.*	n.a.	16.3 x	n.a.	n.a.	9.3 x	6.8 x	6.5 x
P/FCF	9.9 x	20.1 x	3.8 x	7.7 x	37.3 x	10.5 x	8.7 x
P/E	62.6 x	31.5 x	n.a.	154.2 x	7.0 x	5.4 x	5.3 x
P / E adj.*	62.6 x	31.5 x	n.a.	154.2 x	7.0 x	5.4 x	5.3 x
Dividend Yield	0.8 %	0.9 %	n.a.	n.a.	5.7 %	7.4 %	7.5 %
FCF Potential Yield (on market EV)	2.2 %	10.0 %	-1.3 %	11.7 %	21.2 %	23.5 %	25.0 %
*Adjustments made for: -							



Consolidated profit & loss							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024
Sales	204.2	209.1	195.9	203.7	233.0	240.0	247.
Change Sales yoy	-1.0 %	2.4 %	-6.3 %	4.0 %	14.4 %	3.0 %	3.0 %
Increase / decrease in inventory	-0.3	0.0	-0.4	3.1	0.0	0.0	0.0
Own work capitalised	14.1	18.6	7.8	6.2	7.0	7.2	7.4
Total Sales	218.0	227.6	203.2	213.0	240.0	247.2	254.0
Material expenses	101.6	101.6	93.9	103.3	115.3	118.8	122.4
Gross profit	116.3	126.0	109.3	109.6	124.7	128.4	132.2
Gross profit margin	57.0 %	60.3 %	55.8 %	53.8 %	53.5 %	53.5 %	53.5 %
Personnel expenses	64.7	60.2	67.8	57.6	62.9	64.8	66.7
Other operating income	1.9	2.9	4.5	1.7	2.3	2.4	2.5
Other operating expenses	36.4	35.4	36.8	33.8	36.6	36.0	37.
Unfrequent items	0.0	0.0	-1.2	-1.5	0.0	0.0	0.0
EBITDA	17.1	33.3	8.0	18.5	27.5	30.0	30.9
Margin	8.4 %	15.9 %	4.1 %	9.1 %	11.8 %	12.5 %	12.5 %
Depreciation of fixed assets	17.3	24.7	18.9	19.1	19.0	18.8	19.
EBITA	-0.3	8.6	-11.0	-0.7	8.5	11.2	11.4
Amortisation of intangible assets	0.0	2.7	3.0	0.0	0.0	0.0	0.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	-0.3	5.9	-14.0	-0.7	8.5	11.2	11.4
Margin	-0.1 %	2.8 %	-7.1 %	-0.3 %	3.6 %	4.7 %	4.6 %
EBIT adj.	-0.3	5.9	-14.0	-0.7	8.5	11.2	11.4
Interest income	2.8	2.2	2.5	2.6	2.6	2.7	2.8
Interest expenses	1.4	1.8	2.6	1.4	1.4	1.4	1.4
Other financial income (loss)	0.1	-0.3	-0.6	1.6	0.0	0.0	0.0
EBT	1.3	5.9	-14.7	2.2	9.7	12.5	12.8
Margin	0.6 %	2.8 %	-7.5 %	1.1 %	4.2 %	5.2 %	5.2 %
Total taxes	0.4	4.2	0.4	1.8	3.1	4.0	4.
Net income from continuing operations	0.9	1.7	-15.1	0.4	6.6	8.5	8.7
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	0.9	1.7	-15.1	0.4	6.6	8.5	8.7
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	0.9	1.7	-15.2	0.4	6.6	8.5	8.7
Margin	0.4 %	0.8 %	-7.7 %	0.2 %	2.8 %	3.5 %	3.5 %
Number of shares, average	16.2	16.2	16.2	16.2	16.2	16.2	16.2
EPS	0.06	0.11	-0.94	0.02	0.41	0.53	0.54
EPS adj.	0.06	0.11	-0.94	0.02	0.41	0.53	0.54
*Adjustments made for:							

Guidance: Revenues EUR 229-237m, EBITDA EUR 24-28m (2022)


Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Total Operating Costs / Sales	98.4 %	92.9 %	99.1 %	94.8 %	91.2 %	90.5 %	90.5 %
Operating Leverage	n.a.	n.a.	n.a.	-23.8 x	n.a.	10.6 x	0.6 x
EBITDA / Interest expenses	12.3 x	18.5 x	3.1 x	13.2 x	19.7 x	21.4 x	22.1 x
Tax rate (EBT)	28.4 %	71.3 %	-3.0 %	83.1 %	32.0 %	32.0 %	32.0 %
Dividend Payout Ratio	54.1 %	28.4 %	0.0 %	0.0 %	40.0 %	40.3 %	40.1 %
Sales per Employee	165,358	165,992	152,436	155,434	174,306	176,015	177,741





Consolidated balance sheet							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Assets							
Goodwill and other intangible assets	40.8	38.8	39.5	30.1	35.1	42.1	49.1
thereof other intangible assets	30.3	34.1	35.6	30.1	35.1	42.1	49.1
thereof Goodwill	10.4	4.6	3.8	0.0	0.0	0.0	0.0
Property, plant and equipment	29.9	29.2	24.9	25.9	22.9	21.1	18.6
Financial assets	13.4	18.1	16.3	16.8	16.8	16.8	16.8
Other long-term assets	0.0	11.2	0.0	0.0	0.0	0.0	0.0
Fixed assets	84.1	97.3	80.7	72.8	74.8	80.0	84.5
Inventories	11.2	12.4	11.5	16.5	18.9	19.5	20.1
Accounts receivable	19.0	18.1	18.1	19.5	23.0	23.7	24.4
Liquid assets	30.9	30.5	36.1	33.3	34.6	36.7	38.9
Other short-term assets	21.6	28.0	27.6	24.8	24.8	24.8	24.8
Current assets	82.7	89.0	93.3	94.1	101.3	104.6	108.2
Total Assets	166.7	186.3	174.0	166.9	176.1	184.6	192.7
Liabilities and shareholders' equity							
Subscribed capital	16.3	16.3	16.3	15.7	15.7	15.7	15.7
Capital reserve	34.7	34.7	34.3	34.3	34.3	34.3	34.3
Retained earnings	0.0	0.0	0.0	-29.6	-32.4	-28.2	-22.8
Other equity components	-17.7	-19.0	-36.9	-4.8	6.6	8.5	8.7
Shareholders' equity	33.3	32.0	13.7	15.7	24.3	30.3	35.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	33.3	32.0	13.7	15.7	24.3	30.3	35.9
Provisions	17.6	24.0	25.9	36.8	36.8	36.8	36.8
thereof provisions for pensions and similar obligations	16.2	20.6	20.5	19.0	19.0	19.0	19.0
Financial liabilities (total)	39.3	50.2	47.0	47.8	47.8	47.8	47.8
Short-term financial liabilities	0.2	4.1	3.7	11.1	11.1	11.1	11.1
Accounts payable	14.0	14.6	14.1	12.9	13.4	13.8	14.2
Other liabilities	62.6	65.5	73.3	53.8	53.8	55.9	58.0
Liabilities	133.4	154.3	160.3	151.3	151.8	154.3	156.8
Total liabilities and shareholders' equity	166.7	186.3	174.0	166.9	176.1	184.6	192.7


Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Efficiency of Capital Employment							
Operating Assets Turnover	4.4 x	4.6 x	4.8 x	4.2 x	4.5 x	4.8 x	5.1 x
Capital Employed Turnover	3.5 x	2.9 x	4.3 x	4.2 x	4.1 x	4.0 x	3.9 x
ROA	1.1 %	1.8 %	-18.8 %	0.5 %	8.9 %	10.6 %	10.3 %
Return on Capital							
ROCE (NOPAT)	n.a.	2.6 %	n.a.	n.a.	10.9 %	13.0 %	12.5 %
ROE	2.7 %	5.2 %	-66.3 %	2.5 %	33.2 %	31.1 %	26.3 %
Adj. ROE	2.7 %	5.2 %	-66.3 %	2.5 %	33.2 %	31.1 %	26.3 %
Balance sheet quality							
Net Debt	24.6	40.3	31.4	33.4	32.2	30.1	27.8
Net Financial Debt	8.4	19.7	10.9	14.5	13.2	11.1	8.8
Net Gearing	73.9 %	125.9 %	229.7 %	213.5 %	132.5 %	99.2 %	77.4 %
Net Fin. Debt / EBITDA	49.1 %	59.3 %	136.5 %	78.3 %	48.0 %	37.1 %	28.6 %
Book Value / Share	2.1	2.0	0.8	1.0	1.5	1.9	2.2
Book value per share ex intangibles	-0.5	-0.4	-1.6	-0.9	-0.7	-0.7	-0.8





Consolidated cash flow statement							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024
Net income	0.9	1.7	-15.2	0.4	6.6	8.5	8.7
Depreciation of fixed assets	17.3	24.7	18.9	19.1	19.0	18.8	19.5
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	2.7	3.0	0.0	0.0	0.0	0.0
Increase/decrease in long-term provisions	-0.3	4.4	-0.1	-1.6	0.0	0.0	0.0
Other non-cash income and expenses	2.0	0.0	0.0	0.0	2.0	2.0	2.0
Cash Flow before NWC change	19.9	33.5	6.7	17.9	27.6	29.3	30.2
Increase / decrease in inventory	-0.6	-1.2	8.0	<b>-</b> 5.0	-2.4	-0.6	-0.6
Increase / decrease in accounts receivable	0.6	8.0	0.0	-1.3	-3.5	-0.7	-0.7
Increase / decrease in accounts payable	2.8	0.6	-0.4	-1.2	0.5	0.4	0.4
Increase / decrease in other working capital positions	1.5	-10.7	15.6	4.8	0.0	0.0	0.0
Increase / decrease in working capital (total)	4.3	-10.4	16.0	-2.8	-5.4	-0.9	-0.9
Net cash provided by operating activities [1]	24.2	23.1	22.8	15.1	22.2	28.4	29.3
Investments in intangible assets	-9.0	-13.8	-4.0	-1.0	-5.0	-7.0	-7.0
Investments in property, plant and equipment	-9.0	-6.5	-4.8	-7.6	-16.0	-17.0	-17.0
Payments for acquisitions	-3.5	0.0	-2.2	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.3	-1.1	-0.3	0.1	0.0	0.0	0.0
Net cash provided by investing activities [2]	-21.2	-21.4	-11.4	-8.5	-21.0	-24.0	-24.0
Change in financial liabilities	-4.3	11.0	-3.3	0.8	0.0	0.0	0.0
Dividends paid	-1.9	-0.5	-0.5	0.0	0.0	-2.4	-3.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-0.2	-15.2	-1.9	-4.1	0.0	0.0	0.0
Net cash provided by financing activities [3]	-6.4	-4.7	-5.7	-3.2	0.0	-2.4	-3.0
Change in liquid funds [1]+[2]+[3]	-3.5	-3.0	5.1	3.3	1.2	2.1	2.3
Effects of exchange-rate changes on cash	0.5	0.0	-1.0	0.9	0.0	0.0	0.0
Cash and cash equivalent at end of period	21.2	18.1	22.2	27.3	28.6	30.7	32.9

Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Cash Flow							
FCF	6.1	2.8	13.9	6.5	1.2	4.4	5.3
Free Cash Flow / Sales	3.0 %	1.3 %	7.1 %	3.2 %	0.5 %	1.9 %	2.2 %
Free Cash Flow Potential	1.8	9.7	-1.1	9.7	16.6	18.0	18.6
Free Cash Flow / Net Profit	685.7 %	163.8 %	-91.7 %	1769.9 %	18.8 %	52.3 %	61.2 %
Interest Received / Avg. Cash	8.7 %	7.2 %	7.4 %	7.4 %	7.6 %	7.6 %	7.4 %
Interest Paid / Avg. Debt	3.4 %	4.0 %	5.2 %	2.9 %	2.9 %	2.9 %	2.9 %
Management of Funds							
Investment ratio	8.8 %	9.7 %	4.5 %	4.2 %	9.0 %	10.0 %	9.7 %
Maint. Capex / Sales	2.4 %	2.3 %	2.5 %	2.4 %	2.1 %	2.0 %	1.9 %
Capex / Dep	104.2 %	73.9 %	40.4 %	45.0 %	110.5 %	127.7 %	123.1 %
Avg. Working Capital / Sales	8.6 %	7.7 %	8.0 %	9.5 %	11.1 %	12.0 %	12.0 %
Trade Debtors / Trade Creditors	135.7 %	124.4 %	128.3 %	150.9 %	171.4 %	171.4 %	171.4 %
Inventory Turnover	9.1 x	8.2 x	8.2 x	6.3 x	6.1 x	6.1 x	6.1 x
Receivables collection period (days)	34	32	34	35	36	36	36
Payables payment period (days)	50	52	55	46	42	42	42
Cash conversion cycle (Days)	24	24	24	48	53	53	53



7



#### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

8



#### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months			
Francotyp-Postalia	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000FPH9000.htm			



#### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
<b>"_</b> "	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH	- ANALYSED RESEARCH UNIVERSE BY RATING
Poting	Number of stocks


Rating	Number of stocks	% of Universe
Buy	173	81
Hold	35	16
Sell	3	1
Rating suspended	2	1
Total	213	100

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	52	87
Hold	6	10
Sell	0	0
Rating suspended	2	3
Total	60	100

#### PRICE AND RATING HISTORY FRANCOTYP-POSTALIA AS OF 29.04.2022



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Philipp Kaiser Real Estate	+49 40 309537-260 pkaiser@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com
Stefan Augustin	+49 40 309537-168	Eggert Kuls	+49 40 309537-256
Cap. Goods, Engineering	saugustin@warburg-research.com	Engineering	ekuls@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Jonas Blum Telco, Media, Construction	+49 40 309537-240 jblum@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Christian Cohrs	+49 40 309537-175	Oliver Schwarz	+49 40 309537-250
Industrials & Transportation	ccohrs@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Simon Stippig Real Estate	+49 40 309537-265 sstippig@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com	Cansu Tatar Cap. Goods, Engineering	+49 40 309537-248 ctatar@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Marius Fuhrberg	+49 40 309537-185	Robert-Jan van der Horst	+49 40 309537-290
Financial Services  Mustafa Hidir	mfuhrberg@warburg-research.com +49 40 309537-230	Technology  Andreas Wolf	rvanderhorst@warburg-research.com +49 40 309537-140
Automobiles, Car Suppliers	mhidir@warburg-research.com	Software, IT	awolf@warburg-research.com
Thor Höfs	+49 40 309537-255		
Software, IT	thoefs@warburg-research.com		
INSTITUTIONAL EQUI	ITY SALES		
Marc Niemann	+49 40 3282-2660	Maximilian Martin	+49 69 5050-7413
Head of Equity Sales, Germany	mniemann@mmwarburg.com +49 69 5050-7400	Austria, Poland	mmartin@mmwarburg.com +49 40 3282-2695
Klaus Schilling Head of Equity Sales, Germany	kschilling@mmwarburg.com	Christopher Seedorf Switzerland	cseedorf@mmwarburg.com
Tim Beckmann	+49 40 3282-2665		
United Kingdom	tbeckmann@mmwarburg.com		
Lea Bogdanova United Kingdom, Ireland	+49 69 5050-7411 lbogdanova@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415		
Scandinavia, Austria	jbuchmueller@mmwarburg.com		
Alexander Eschweiler Germany, Luxembourg	+49 40 3282-2669	Sophie Hauer Roadshow/Marketing	+49 69 5050-7417 shauer@mmwarburg.com
Matthias Fritsch	aeschweiler@mmwarburg.com +49 40 3282-2696	Juliane Niemann	+49 40 3282-2694
United Kingdom	mfritsch@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING			
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading	omerckel@mmwarburg.com	Sales Trading	mmagiera@mmwarburg.com
Elyaz Dust	+49 40 3282-2702	Bastian Quast	+49 40 3282-2701
Sales Trading	edust@mmwarburg.com	Sales Trading	bquast@mmwarburg.com
Michael Ilgenstein Sales Trading	+49 40 3282-2700 milgenstein@mmwarburg.com	Jörg Treptow Sales Trading	+49 40 3282-2658 jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	<b>Dr. Christian Jasperneite</b> Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be f	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	Refinitiv	www.refinitiv.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		apitanq.oom
For access please conta			
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com
			-